DiaCarta Receives NCI Contract for a Circulating Free DNA (cfDNA) Test to Monitor Radiation Response in Cancer Patients
California-based molecular diagnostics company DiaCarta, Inc., has received a SBIR contract from the National Cancer Institute (NCI). This contract will fund a collaborative program between DiaCarta and University of Florida Health Cancer Center to convert RadTox QuantiDNATM into a cutting-edge test that monitors radiation response in cancer patients.
DiaCarta, which has clinical laboratory sites located in the San Francisco Bay area and Nanjing, China, has developed and commercialized a suite of highly sensitive and specific technologies and products for the detection and quantitation of nucleic acids directly from bodily fluids without DNA purification. With support from the NCI, DiaCarta will employ its QuantiDNATM to monitor circulating free DNA (cfDNA), a patented DNA biomarker, directly from patient plasma during radiation therapy. Currently, there exists no reliable methodology for determining radiation response during radiotherapy. Utilizing blood specimens from patients undergoing radiotherapy for prostate cancer at the UF Davis Cancer Center and the UF Health Proton Therapy Institute, DiaCarta will fully validate their current RadTox QuantiDNATM product as a laboratory developed test (LDT) and pursue regulatory approval for global distribution.
“This will be a breakthrough ‘first-in-class’ IVD test in the field of radiation therapy and the first cfDNA test to be supported by the NCI for real-time detection of tumor and normal tissue responses to radiation. It is a significant milestone in the field of patient monitoring of radiation therapy response,” said Aiguo Zhang, PhD, CEO of DiaCarta. “Radiation treatment is required by 70% of cancer patients,” he said. “However, despite decades of advances in cancer care and technology, there remain many fundamental challenges affecting safe and efficacious delivery of radiation treatment. Our QuantiDNATM test has the potential to overcome these challenges.”
“We are fulfilling an unmet medical need in cancer radiation therapy by enabling the direct monitoring of side effect severity and tumor response within days of treatment initiation,” said Paul Okunieff, MD, chair of the Department of Radiation Oncology at the UFHCC. “This NCI-supported contract puts us in a powerful position to begin development of quantitative and personalized ‘liquid biopsies.’ It is a very exciting opportunity for the UF Department of Radiation Oncology and the Okunieff Lab to make a real difference in the quality and safety of care for individual cancer patients.”
“DiaCarta is committed to precision medicine with our strong expertise in biomarker discovery and breakthrough technologies. RadTox QuantiDNATM has the potential to make personalized medicine in radiation oncology a reality. We are very excited to collaborate with the UFHCC, one of the largest cancer centers in the U.S., to validate the novel test and potentially increase the quality and safety of radiation therapy for its patients,” said Dr. Zhang.
DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy, today announced the appointment of Jack Kaye, retired Partner with Deloitte LLP, as an independent board member who will serve as the Chairman of the Company’s Audit Committee.
DiaCarta Enters a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to Develop Cancer Tests based on its Novel XNA Technology
DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy today announced that the company, under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health, will collaborate on the evaluation and development of DiaCarta’s proprietary xeno-nucleic acid (XNA) molecular clamping technology. NCI and DiaCarta will collaborate on the following projects: (1) the investigation of low frequency mutation events in cancers and rare diseases using DiaCarta’s proprietary xeno-nucleic acid (XNA) molecular clamping technology, and (2) the development of XNA probes for in situ cancer cell detection. The duration of the CRADA will be 2 years from the effective start date.
DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy announced today that the company has developed a novel test to detect the newest COVID-19 Omicron variant, based on its proprietary XNA technology.
DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel virology and oncology tests, mourns the passing of Michael “Mike” J. Powell, Ph.D., Chief Scientific Officer of DiaCarta.
DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy today announced that its new QuantiVirus™ SARS-CoV-2 Variant Detection Test received the CE/IVD marking and therefore, can now be commercialized within the EU and rest of the world. This new test screens for the SARS-CoV-2 virus and simultaneously identifies and differentiates all the new mutating COVID 19 variants including the Alpha (UK), Beta (S. Africa), Gamma (Brazil), Delta (India), Delta Plus (India), Epsilon (California) and the Kappa (India) variants.